吸入用乙酰半胱氨酸溶液雾化吸入对AECOPD患者症状改善及血清细胞因子水平变化的影响  

Effect of Aerosol Inhalation of Acetylcysteine Solution on Improvement of Symptoms and Changes of Serum Level of Cytokines in Patients with AECOPD

作　　者：罗佳薇 LUO Jia-wei(Department of Pharmacy,Wuhan Gold and Silver Tan Hospital(Wuhan Hospital for Infectious Diseases),Wuhan 430023,China)

机构地区：[1]武汉市金银潭医院(武汉市传染病医院)药学部,湖北武汉430023

出　　处：《药物生物技术》2023年第4期384-388,共5页Pharmaceutical Biotechnology

摘　　要：探讨吸入用乙酰半胱氨酸溶液雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)患者症状改善及血清细胞因子水平变化的影响。采用随机数字表法将180例2018年5月至2022年5月本院收治的AECOPD患者分为对照组(90例)和试验组(90例)。两组均给予常规基础治疗,对照组在此基础上给予吸入用复方异丙托溴铵溶液进行治疗,试验组在对照组基础上给予吸入用乙酰半胱氨酸溶液进行治疗,两组均持续治疗2 w。比较两组治疗2 w后疗效,症状改善情况,治疗前、治疗2 w后肺功能相关指标、血清细胞因子水平及治疗期间不良反应发生情况。与对照组比较,试验组治疗2 w后的总有效率较高(87.78%vs 72.22%,P<0.05)。与对照组比较,试验组肺部哮鸣音、咳痰、喘息、咳嗽缓解时间较短(P<0.05)。与治疗前比较,治疗2 w后,两组深吸气量(IC)、最大自主通气量(MVV)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)均升高,试验组高于对照组(P<0.05);两组呼出气一氧化氮(FeNO)及血清克拉拉细胞蛋白16(CC16)、8-羟基脱氧鸟苷(8-OHdG)、白三烯B4(LTB4)、内皮素-1(ET-1)、白细胞介素-6(IL-6)水平均降低,试验组低于对照组(P<0.05)。治疗期间,对照组、试验组不良反应总发生率分别为10.00%、7.78%,两组不良反应总发生率比较差异无统计学意义(P>0.05)。吸入用乙酰半胱氨酸溶液雾化吸入可明显改善AECOPD患者临床症状及肺功能,并可调节机体血清细胞因子水平,减轻炎症反应,疗效显著,安全性良好。To investigate the effect of aerosol inhalation of acetylcysteine solution on improvement of symptoms and changes of serum level of cytokine in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD),180 cases of patients with AECOPD admitted to the authors hospital from May 2018 to May 2022 were divided into the control group(90 cases)and the test group(90 cases)by random number table method.Both groups were given routine basic treatment,the control group was given inha⁃lation of compound ipratropium bromide solution on this basis for treatment,and the test group was given inhalation of acetylcysteine solution on the basis of the control group,both groups were treated for 2 weeks.The curative effect after 2 weeks of treatment,symp⁃tom improvement,lung function related indicators,serum level of cytokines before and after 2 weeks of treatment and adverse reac⁃tions during treatment were compared between the two groups.Compared with the control group,the total effective rate of the test group was higher after 2 weeks of treatment(87.78%vs 72.22%,P<0.05).Compared with the control group,the relief times of lung wheeze,expectoration,wheeze and cough in the lungs of the test group was shorter(P<0.05).Compared with that before treat⁃ment,after 2 weeks of treatment,the deep inspiratory volume(IC),maximum voluntary ventilation volume(MVV),forced expiratory volume in the first second(FEV1)and forced vital capacity(FVC)in the two groups increased,and the test group was higher than the control group(P<0.05).The levels of exhaled nitric oxide(FeNO)and serum Clara cell protein 16(CC16),8⁃hydroxydeox⁃yguanosine(8⁃OHdG),leukotriene B4(LTB4),endothelin⁃1(ET⁃1),interleukin⁃6(IL⁃6)in both groups decreased,and those in the test groups were lower than those in the control group(P<0.05).During treatment,the total incidence of adverse reactions in the control group and the test group were 10.00%and 7.78%respectively,and there was no significant difference between the two groups(P>0.05).Ae

关 键 词：慢性阻塞性肺疾病急性加重期 吸入用乙酰半胱氨酸溶液 吸入用复方异丙托溴铵溶液 症状 肺功能 细胞因子 安全性 

分 类 号：R56[医药卫生—呼吸系统]